Open and closed fibrous cap thickness measurements for HR and LR carotid arterial wall measurements.

<p>* = p-value for paired t-test between HR scan and LR scan.</p><p>† = p-value for paired t-test between HR rescan and LR rescan using the closed segmentation method.</p><p>‡ = p-value for Levene’s test between HR and LR measurements for the corresponding segmentation. HR = high resolution; LR = low resolution; ICC = intraclass correlation coefficient; SD = standard deviation.</p><p>Data are presented as mean with ± SD. ICCs are given with the corresponding 95% confidence interval.</p

Flowchart describing the study cohort and the patients included in this study.

<p>Flowchart describing the study cohort and the patients included in this study.</p

Open and closed segmented calcified surface area measurements for HR and LR carotid arterial wall measurements.

<p>* = p-value for paired t-test between HR scan and LR scan.</p><p>† = p-value for paired t-test between HR rescan and LR rescan using the closed segmentation method.</p><p>‡ = p-value for Levene’s test between HR and LR measurements for the corresponding segmentation. HR = high resolution; LR = low resolution; ICC = intraclass correlation coefficient; CV = coefficient of variation; SD = standard deviation.</p><p>Data are presented as number with percentage or mean with SD. ICCs are given with the corresponding 95% confidence interval.</p

Relationships of MCVEs to biomarker levels measured after 1 year of treatment.^a

<p>HR is hazard ratio, CI is confidence interval, LDL is low-density lipoprotein, HDL is high-density lipoprotein, HMW is high molecular weight, hsCRP is high-sensitivity C-reactive protein, Lp-PLA2 is lipoprotein-associated phospholipase A2, MCP-1 is monocyte chemotactic protein-1, MMP-9 is matrix metalloproteinase-9, MPO is myeloperoxidase, Nt-pro-BNP is N-terminal fragment of pro-B-type natriuretic peptide, sRAGE is soluble receptor for advanced glycation end-products, sCD40L is soluble CD40 ligand, sICAM-1 is soluble intercellular adhesion molecule, and sVCAM-1 is soluble vascular cell adhesion molecule-1.</p>a<p>Individuals who experienced a MCVE within 1 year of follow-up (n = 34) were not included in the present analyses.</p>b<p>Hazard ratio associated with doubling the concentration and adjusting for age, gender, and treatment effect.</p>c<p><i>P</i> = 0.05 for treatment by biomarker interaction.</p><p>Relationships of MCVEs to biomarker levels measured after 1 year of treatment.^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0114519#nt111" target="_blank">a</a>}</p

Non-lipid biomarker levels at time of randomization.^a

<p>Values are median (range). Atv is atorvastatin, HMW is high molecular weight, hsCRP is high-sensitivity C-reactive protein, Lp-PLA2 is lipoprotein-associated phospholipase A2, MCP-1 is monocyte chemotactic protein-1, MMP-9 is matrix metalloproteinase-9, MPO is myeloperoxidase, Nt-pro-BNP is N-terminal fragment of pro-B-type natriuretic peptide, sRAGE is soluble receptor for advanced glycation end-products, sCD40L is soluble CD40 ligand, sICAM-1 is soluble intercellular adhesion molecule, and sVCAM-1 is soluble vascular cell adhesion molecule-1.</p>a<p>At the time of randomization, all participants had been on 10 mg atorvastatin for at least 8 weeks.</p>b<p><i>P</i>-value for patients who experienced an event versus those who did not in the biomarker subgroup.</p><p>Non-lipid biomarker levels at time of randomization.^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0114519#nt105" target="_blank">a</a>}</p

Relationships of MCVEs to biomarker levels measured at time of randomization.^a

<p>HR is hazard ratio, CI is confidence interval, LDL is low-density lipoprotein, HDL is high-density lipoprotein, HMW is high molecular weight, hsCRP is high-sensitivity C-reactive protein, Lp-PLA2 is lipoprotein-associated phospholipase A2, MCP-1 is monocyte chemotactic protein-1, MMP-9 is matrix metalloproteinase-9, MPO is myeloperoxidase, Nt-pro-BNP is N-terminal fragment of pro-B-type natriuretic peptide, sRAGE is soluble receptor for advanced glycation end-products, sCD40L is soluble CD40 ligand, sICAM-1 is soluble intercellular adhesion molecule, and sVCAM-1 is soluble vascular cell adhesion molecule-1.</p>a<p>At the time of randomization, all participants had been on 10 mg atorvastatin for at least 8 weeks.</p>b<p>Hazard ratio associated with doubling the concentration and adjusting for age, gender, and treatment effect. Treatment interaction by individual biomarker is not significant for all biomarkers analyzed.</p><p>Relationships of MCVEs to biomarker levels measured at time of randomization.^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0114519#nt108" target="_blank">a</a>}</p

Patients' characteristics at time of randomization.^a

<p>Continuous variables are mean (standard deviation). Atv is atorvastatin, LDL is low-density lipoprotein, and HDL is high-density lipoprotein.</p>a<p>At the time of randomization, all participants had been on 10 mg atorvastatin for at least 8 weeks.</p>b<p><i>P</i>-value for patients who experienced an event versus those who did not in the biomarker subgroup.</p><p>Patients' characteristics at time of randomization.^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0114519#nt102" target="_blank">a</a>}</p

Scan parameters for the HR and LR carotid arterial wall dimension measurements.

<p>* Scan times at heart rate of 60 min^-1</p><p>HR = high resolution; LR = low resolution; TSE = turbo spin-echo, FFE = fast field echo, FOV = field of view, DIR = double inversion-recovery, NEX = number of excitations.</p

Number of identified carotid plaque components with corresponding scan-rescan mismatch.

<p>Data are presented as number.</p

Within-reader and between-reader reproducibility for the HR and LR carotid arterial wall component measurements.

<p>Data are presented as mean with (95% CI). Last column contains p-value for Levene’s test between HR and LR measurements. HR = high resolution; LR = low resolution.</p